rEVO Biologics, Inc.-Strategic SWOT Analysis Review

rEVO Biologics, Inc.-Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

Business description-A detailed description of the company’s operations and business divisions.

Corporate strategy-GlobalData’s summarization of the company’s business strategy.

SWOT analysis-A detailed analysis of the company’s strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives’ employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list of key locations and subsidiaries of the company, including contact details.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Highlights

rEVO Biologics (rEVO), a subsidiary of LFB Biotechnologies S.A.S is a biopharmaceutical company that develops and commercializes specialty therapeutics for the treatment of rare diseases. It develops products for treating cancer, and hematology, autoimmune and genetic diseases. The company’s lead product, ATryn is a plasma-free antithrombin (recombinant) concentrate indicated for the treatment of hereditary anti thrombin deficiency. rEVO is also developing ATryn for the treatment of preeclampsia between weeks 24-28 of pregnancy, and for the treatment of preeclampsia between weeks 29-33 of pregnancy; and rhAAT, a recombinant alpha-1 antitrypsin for hereditary emphysema. rEVO is headquartered in Framingham, Massachusetts, the US.

rEVO Biologics, Inc. Key Recent Developments

Oct 22, 2015: study reports significant increase in incidence of preeclampsia, a potentially life-threatening pregnancy complication

Feb 03, 2015: rEVO Biologics Provides Grant to Yale University to Establish a Center of Advancement for Preeclampsia

Feb 03, 2015: New Yale Center to advance understanding of life-threatening preeclampsia

Feb 03, 2015: rEVO Biologics Provides Grant to Yale University to Establish a Center of Advancement for Preeclampsia

Reasons To Buy

Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.

Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.

Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.

Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.